menu

MYR Pharmaceuticals — Treatment of HBV & HDV Infections

Career opportunities — Join our team! Privacy Policy

Bulevirtide

HomeBulevirtide
HomeBulevirtide

Learn more about our medicine and its unique mechanism of action 

Indication

Hepatitis delta is the most severe form of viral hepatitis. It is caused by HDV, a small RNA virus, which requires helper functions from HBV for virion assembly and propagation, and uses the HBV envelope for virus release and infection of new cells. More...

Mechanism of action

Bulevirtide is a novel drug candidate for treatment of chronic hepatitis B and chronic hepatitis delta and was originally developed by Professor Stephan Urban (University of Heidelberg, Germany). More...

NTCP

Bulevirtide is the first drug in clinical development specifically targeting an important liver protein – NTCP, or sodium taurocholate co-transporting polypeptide. More...